吸附性血液净化装置成功治疗双侧腿部难治性溃疡。

IF 1.8 Q3 SURGERY

Plastic and Reconstructive Surgery Global Open Pub Date : 2025-09-22 eCollection Date: 2025-09-01 DOI:10.1097/GOX.0000000000007127

Asako Iida, Goh Akiyama, Kaoruko Matsunami, Rei Ogawa

{"title":"吸附性血液净化装置成功治疗双侧腿部难治性溃疡。","authors":"Asako Iida, Goh Akiyama, Kaoruko Matsunami, Rei Ogawa","doi":"10.1097/GOX.0000000000007127","DOIUrl":null,"url":null,"abstract":"Chronic limb-threatening ischemia (CLTI) is the most advanced stage of lower extremity artery disease. Patients with CLTI are often unsuitable for revascularization and thus have limited treatment options. In 2020, Japan approved Rheocarna for such cases. Rheocarna is an adsorptive blood-purification device that removes low-density lipoprotein cholesterol and fibrinogen. We presented the case of a 63-year-old man with chronic kidney disease and diabetes mellitus who presented with severe and progressing refractory ulcers. Angiography revealed severe arterial calcification, indicating CLTI. No targets for standard revascularization treatment were found. Together with wound care and hyperbaric oxygen, 20 Rheocarna treatment sessions improved circulation and ulcer healing, thus avoiding amputation. Thus, Rheocarna may be a promising therapy for CLTI patients who are ineligible for revascularization. Further studies are needed to validate its efficacy.","PeriodicalId":20149,"journal":{"name":"Plastic and Reconstructive Surgery Global Open","volume":"13 9","pages":"e7127"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12453316/pdf/","citationCount":"0","resultStr":"{\"title\":\"Successful Treatment of Refractory Bilateral Leg Ulcers With an Adsorptive Blood-Purification Device.\",\"authors\":\"Asako Iida, Goh Akiyama, Kaoruko Matsunami, Rei Ogawa\",\"doi\":\"10.1097/GOX.0000000000007127\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic limb-threatening ischemia (CLTI) is the most advanced stage of lower extremity artery disease. Patients with CLTI are often unsuitable for revascularization and thus have limited treatment options. In 2020, Japan approved Rheocarna for such cases. Rheocarna is an adsorptive blood-purification device that removes low-density lipoprotein cholesterol and fibrinogen. We presented the case of a 63-year-old man with chronic kidney disease and diabetes mellitus who presented with severe and progressing refractory ulcers. Angiography revealed severe arterial calcification, indicating CLTI. No targets for standard revascularization treatment were found. Together with wound care and hyperbaric oxygen, 20 Rheocarna treatment sessions improved circulation and ulcer healing, thus avoiding amputation. Thus, Rheocarna may be a promising therapy for CLTI patients who are ineligible for revascularization. Further studies are needed to validate its efficacy.\",\"PeriodicalId\":20149,\"journal\":{\"name\":\"Plastic and Reconstructive Surgery Global Open\",\"volume\":\"13 9\",\"pages\":\"e7127\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12453316/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Plastic and Reconstructive Surgery Global Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/GOX.0000000000007127\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Plastic and Reconstructive Surgery Global Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/GOX.0000000000007127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

摘要

慢性肢体威胁缺血（CLTI）是下肢动脉疾病的最晚期。CLTI患者通常不适合进行血运重建术，因此治疗选择有限。2020年，日本批准了Rheocarna用于此类病例。Rheocarna是一种吸附性血液净化装置，可去除低密度脂蛋白、胆固醇和纤维蛋白原。我们提出的情况下，63岁的男子慢性肾脏疾病和糖尿病谁提出了严重和进展难治性溃疡。血管造影显示严重动脉钙化，提示CLTI。未发现标准血运重建治疗的靶点。与伤口护理和高压氧一起，20次Rheocarna治疗改善了血液循环和溃疡愈合，从而避免了截肢。因此，Rheocarna可能是一个有希望的治疗CLTI患者谁是不符合血运重建术。需要进一步的研究来验证其有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Successful Treatment of Refractory Bilateral Leg Ulcers With an Adsorptive Blood-Purification Device.

Chronic limb-threatening ischemia (CLTI) is the most advanced stage of lower extremity artery disease. Patients with CLTI are often unsuitable for revascularization and thus have limited treatment options. In 2020, Japan approved Rheocarna for such cases. Rheocarna is an adsorptive blood-purification device that removes low-density lipoprotein cholesterol and fibrinogen. We presented the case of a 63-year-old man with chronic kidney disease and diabetes mellitus who presented with severe and progressing refractory ulcers. Angiography revealed severe arterial calcification, indicating CLTI. No targets for standard revascularization treatment were found. Together with wound care and hyperbaric oxygen, 20 Rheocarna treatment sessions improved circulation and ulcer healing, thus avoiding amputation. Thus, Rheocarna may be a promising therapy for CLTI patients who are ineligible for revascularization. Further studies are needed to validate its efficacy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Plastic and Reconstructive Surgery Global Open SURGERY-

CiteScore

2.20

自引率

13.30%

发文量

1584

审稿时长

10 weeks

期刊介绍： Plastic and Reconstructive Surgery—Global Open is an open access, peer reviewed, international journal focusing on global plastic and reconstructive surgery.Plastic and Reconstructive Surgery—Global Open publishes on all areas of plastic and reconstructive surgery, including basic science/experimental studies pertinent to the field and also clinical articles on such topics as: breast reconstruction, head and neck surgery, pediatric and craniofacial surgery, hand and microsurgery, wound healing, and cosmetic and aesthetic surgery. Clinical studies, experimental articles, ideas and innovations, and techniques and case reports are all welcome article types. Manuscript submission is open to all surgeons, researchers, and other health care providers world-wide who wish to communicate their research results on topics related to plastic and reconstructive surgery. Furthermore, Plastic and Reconstructive Surgery—Global Open, a complimentary journal to Plastic and Reconstructive Surgery, provides an open access venue for the publication of those research studies sponsored by private and public funding agencies that require open access publication of study results. Its mission is to disseminate high quality, peer reviewed research in plastic and reconstructive surgery to the widest possible global audience, through an open access platform. As an open access journal, Plastic and Reconstructive Surgery—Global Open offers its content for free to any viewer. Authors of articles retain their copyright to the materials published. Additionally, Plastic and Reconstructive Surgery—Global Open provides rapid review and publication of accepted papers.